1,720,992 research outputs found
Efficacia della terapia con atorvastatina ad alto dosaggio sulla protezione della funzione endoteliale e riduzione dei biomarkers infiammatori nei pazienti con STEMI
No full textSingle Centre pilot study on mechanism of vascular effects of carfilzomib in patients with multiple myeloma; preliminary results on endothelial dysfunction and vascular stiffness.
No full textPrognostic value of the absolute lymphocyte count in patients admitted for acute heart failure
No full textLow relative lymphocyte count is an important prognostic marker in acute heart failure (AHF); however, it could be influenced by other abnormalities in white cells count. Our purpose is to evaluate if low absolute lymphocyte count (ALC) is an independent predictor of events in patients with AHF
Cardiorenal Interactions
No full textRecently, there has been increased appreciation of the identification and management of comorbidities in heart failure patients, and for therapies targeting conventional heart failure signs and symptoms. Renal dysfunction is common in patients with heart failure and is associated with high morbidity and mortality. Early identification of renal damage through novel biomarkers and the use of new pharmacological strategies aimed at preserving renal function may represent an important objective in the treatment. This article reviews the epidemiology and pathophysiology of cardiorenal syndrome in heart failure, and highlights novel biomarkers and improved therapies targeting renal dysfunction
[Indications for statin therapy in patients with acute coronary syndrome of ischemic origin]
No full textRecent evidence has increasingly demonstrated that statins, besides reducing cholesterol levels, are as effective as other therapeutic approaches in the treatment of patients with acute coronary syndromes. Appropriate control of cardiovascular risk factors accounts for 44% of the overall reduction in mortality. The decrease in plasma cholesterol concentrations, however, remains the most effective therapeutic target, leading to a -24% reduction of total mortality. Statins have proved to be effective within the first few weeks after an acute coronary event. As a consequence, their use is recommended by current guidelines (class IB) in patients with non-ST-elevation myocardial infarction. Data from recent trials suggest that early statin therapy is a reasonable option for patients with ST-elevation myocardial infarction (class IA recommendation)
Effects of Rosuvastatin vs. Atorvastatin at high doses acutely after STEMI: endothelial dysfunction and inflammatory biomarkers evaluation
No full textEffect of High dose of atorvastatin versus moderate dose on endothelial function and inflammatory biomarkers in patients with STEMI
No full textEffect of High dose of atorvastatin versus moderate dose on endothelial function and inflammatory biomarkers in patients with STEMI
No full text- …
